Edoxaban
- Generic Name
- Edoxaban
- Brand Names
- Lixiana, Savaysa, Roteas
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O4S
- CAS Number
- 480449-70-5
- Unique Ingredient Identifier
- NDU3J18APO
- Background
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...
- Indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...
- Associated Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
- Associated Therapies
- -
Effects of Edoxaban on Platelet Aggregation
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 70
- Registration Number
- NCT05122455
- Locations
- 🇧🇷
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT05035277
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Oslo Univesity Hospital - Ullevål, Oslo, Norway
🇳🇴Oslo University Hospital - Rikshospitalet, Oslo, Norway
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55759
- Registration Number
- NCT05022563
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Sungkyunkwan University, Suwon-si, Korea, Republic of
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 1000000
- Registration Number
- NCT04878497
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 5000
- Registration Number
- NCT04747496
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Changzhou No.2 People'S Hospital, Changzhou, Jiangsu, China
🇨🇳Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Kyushu University
- Target Recruit Count
- 74
- Registration Number
- NCT04730037
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Malmö University
- Target Recruit Count
- 216
- Registration Number
- NCT04662515
- Locations
- 🇸🇪
Skåne University Hospital, Helsingborg, Sweden
🇸🇪Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö, Sweden
Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04618913
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Daiichi Sankyo Turkey, a Daiichi Sankyo Company
- Target Recruit Count
- 1053
- Registration Number
- NCT04594915
- Locations
- 🇹🇷
İstanbul Mehmet Akif Ersoy Göğüs Kalp ve Damar Cerrahisi EAH, Istanbul, Turkey
🇹🇷Tekirdağ Şehir Hastanesi, Tekirdağ, Turkey
🇹🇷Başkent University Alanya Practice and Research Hospital, Cardiology Clinic, Antalya, Alanya, Turkey
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 666
- Registration Number
- NCT04519944
- Locations
- 🇩🇪
Zentralklinik Bad Berka, Bad Berka, Germany
🇩🇪Kerckhoff-Klinik GmbH, Bad Nauheim, Germany
🇩🇪SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald, Bad Friedrichshall, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.